First Therapeutic Vaccine for Genital Herpes Reduces Signs of Infection for One Year
JUN 22, 2016 | SARAH ANWAR
Dr. Fife presented his team’s research at the ASM Microbe 2016 Conference, in Boston, Massachusetts. Their clinical trial included 310 participants known to have chronic, recurrent genital herpes. The patients were injected with six different doses of the three injections, 21 days apart. Over the course of one year, patients were tested for signs of body response to the herpes virus, whether through visible signs of viral shedding, lesions, or immune response to the virus. The frequency of observable signs of the virus significantly decreased after treatment with GEN-003, while immune response data is still under analysis.
Dr. Fife explained GEN-003’s functions to Contagion.
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512